NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $57.52 -0.74 (-1.27%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$58.63 +1.11 (+1.93%) As of 11/20/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vericel Stock (NASDAQ:VCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vericel alerts:Sign Up Key Stats Today's Range$57.33▼$59.4950-Day Range$38.79▼$59.4552-Week Range$28.95▼$59.75Volume582,315 shsAverage Volume970,316 shsMarket Capitalization$2.94 billionP/E Ratio89.88Dividend YieldN/APrice Target$62.00Consensus RatingModerate Buy Company Overview Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns. The company traces its roots to Aastrom Biosciences and adopted the Vericel name in 2014. Nick Colangelo serves as its chief executive officer.AI Generated. May Contain Errors. Read More Vericel Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreVCEL MarketRank™: 2.80790248003 of 5 starsVericel scored higher than 56% of companies evaluated by MarketBeat, and ranked 391st out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingVericel has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Vericel is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageVericel has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vericel's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth25.64% Earnings GrowthEarnings for Vericel are expected to grow by 25.64% in the coming year, from $0.78 to $0.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is 89.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is 89.88, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.Price to Book Value per Share RatioVericel has a P/B Ratio of 7.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.34% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 9.83.Change versus previous monthShort interest in Vericel has recently increased by 2.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.09 News SentimentVericel has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vericel this week, compared to 3 articles on an average week.Search Interest7 people have searched for VCEL on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows2 people have added Vericel to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,701,078.00 in company stock.Percentage Held by Insiders7.60% of the stock of Vericel is held by insiders.Percentage Held by InstitutionsVericel has minimal institutional ownership at this time.Read more about Vericel's insider trading history. Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCEL Stock News HeadlinesVericel Earnings Call Signals Broad Growth and Stronger ProfitsNovember 15, 2026 | tipranks.comVericel Corporation (NASDAQ:VCEL) Stock Rated "Buy" by Sell-Side AnalystsNovember 15, 2026 | americanbankingnews.comPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026November 13, 2026 | globenewswire.comVericel (NASDAQ:VCEL) Director Sells 2,000 Shares of StockNovember 13, 2026 | insidertrades.comVericel (NASDAQ:VCEL) Sets New 1-Year High on Analyst UpgradeNovember 13, 2026 | americanbankingnews.comVericel Corporation 2026 Q3 - Results - Earnings Call PresentationNovember 10, 2026 | seekingalpha.comVericel (NASDAQ:VCEL) Insider Sells 1,500 Shares of StockNovember 7, 2026 | insidertrades.comSee More Headlines VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $36.01 at the start of the year. Since then, VCEL shares have increased by 59.7% and is now trading at $57.52. How were Vericel's earnings last quarter? Vericel Corporation (NASDAQ:VCEL) posted its earnings results on Thursday, November, 5th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel's quarterly revenue was up 26.5% on a year-over-year basis. Read the conference call transcript. Who are Vericel's major shareholders? Vericel's top institutional investors include State Street Corp (6.28%), Congress Asset Management Co. (4.98%), Aberdeen Group plc (4.23%) and William Blair Investment Management LLC (3.83%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Robert L Md Zerbe, Paul K Wotton, Joseph Anthony Mara Jr, Steven C Gilman, Sean C Flynn, Jonathan Siegal and Michael Halpin. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), GE Aerospace (GE), Exelixis (EXEL) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/05/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VCEL's financial health is in the Green zone, according to TradeSmith. VCEL has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VCEL CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees398Year Founded1989Price Target and Rating Average Price Target for Vericel$62.00 High Price Target$75.00 Low Price Target$46.00 Potential Upside/Downside+7.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.64 Trailing P/E Ratio89.88 Forward P/E Ratio58.69 P/E GrowthN/ANet Income$16.52 million Net Margins10.27% Pretax Margin10.54% Return on Equity9.09% Return on Assets6.68% Debt Debt-to-Equity RatioN/A Current Ratio5.13 Quick Ratio4.82 Sales & Book Value Annual Sales$324.17 million Price / Sales9.05 Cash Flow$0.56 per share Price / Cash Flow103.55 Book Value$7.53 per share Price / Book7.64Miscellaneous Outstanding Shares51,030,000Free Float47,152,000Market Cap$2.94 billion OptionableOptionable Beta1.08 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:VCEL) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA $4,120 Caterpillar winner in 2 days, now $7 for Black FridayMarkham Trading's Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 for access...TradeWins | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.